Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowEli Lilly and Co.'s lung cancer treatment Alimta is poised for continued growth based on recently released study data, according to a Credit Suisse analyst report.
Indianapolis-based Lilly presented study results earlier this month on the use of Alimta as a maintenance therapy to keep the cancer from progressing after the drug also was used as a first option to treat patients.
Alimta is already approved to treat patients with a subset of non-small cell lung cancer as both a first-line treatment or a second option when the disease progresses. It also can be used as a maintenance treatment, but Lilly is seeking to update the drug's label to make it clear that Alimta can be used in this role when it also was used as a first-line treatment.
Analyst Catherine Arnold said in a research note Wednesday that other therapies will replace Alimta as a first-line treatment for the disease, but it will still treat a majority of the patients. She also said study results showed a strong improvement in progression-free survival when Alimta is used as a maintenance treatment, and the new data "reaffirms our positive view on the continued growth of Alimta."
Alimta is one of Lilly's top-selling drugs. It generated about $580 million in sales in the first quarter and $2.21 billion last year.
Please enable JavaScript to view this content.